$18.21
0.804.57%
Last update: Nov 6, 1:05 PM
Braveheart Bio Inc
BRVENASDAQ
The average analyst price target for Braveheart Bio is $45.25, 148.5% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $40 to $48. The latest change came on Aug 31, 2026, when Goldman Sachs initiated coverage of Braveheart Bio with a Buy rating and a $48 price target.
Price Target Range — 2 Quarters
Analyst Consensus — 5 Analysts
Rating Trend — Last 9 Months
